Literature DB >> 22915644

Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Simon F De Meyer1, Alexander S Savchenko, Michael S Haas, Daphne Schatzberg, Michael C Carroll, Alexandra Schiviz, Barbara Dietrich, Hanspeter Rottensteiner, Friedrich Scheiflinger, Denisa D Wagner.   

Abstract

Coronary heart disease is a major cause of death in the western world. Although essential for successful recovery, reperfusion of ischemic myocardium is inevitably associated with reperfusion injury. To investigate a potential protective role of ADAMTS13, a protease cleaving von Willebrand factor multimers, during myocardial ischemia/reperfusion, we used a mouse model of acute myocardial infarction. We found that Adamts13(-/-) mice developed larger myocardial infarctions than wild-type control mice, whereas treatment of wild-type mice with recombinant human ADAMTS13 (rhADAMTS13) led to smaller infarctions. The protective effect of ADAMTS13 was further confirmed by a significant reduction of cardiac troponin-I release and less myocardial apoptosis in mice that received rhADAMTS13 compared with controls. Platelets adherent to the blood vessel wall were observed in few areas in the heart samples from mice treated with vehicle and were not detected in samples from mice treated with rhADAMTS13. However, we observed a 9-fold reduction in number of neutrophils infiltrating ischemic myocardium in mice that were treated with rhADAMTS13, suggesting a potent anti-inflammatory effect of ADAMTS13 during heart injury. Our data show that ADAMTS13 reduces myocardial ischemia/reperfusion injury in mice and indicate that rhADAMTS13 could be of therapeutic value to limit myocardial ischemia/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915644      PMCID: PMC3537313          DOI: 10.1182/blood-2012-06-439935

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

Authors:  David G Motto; Anil K Chauhan; Guojing Zhu; Jonathon Homeister; Colin B Lamb; Karl C Desch; Weirui Zhang; Han-Mou Tsai; Denisa D Wagner; David Ginsburg
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience.

Authors:  Leo J McCarthy; Constance F M Danielson; Elaine M Skipworth; Shelley L Peters; Charles C Miraglia; Asok C Antony
Journal:  Ther Apher       Date:  2002-02

Review 3.  The role of neutrophils in myocardial ischemia-reperfusion injury.

Authors:  J E Jordan; Z Q Zhao; J Vinten-Johansen
Journal:  Cardiovasc Res       Date:  1999-09       Impact factor: 10.787

4.  High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women.

Authors:  Helena M Andersson; Bob Siegerink; Brenda M Luken; James T B Crawley; Ale Algra; David A Lane; Frits R Rosendaal
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

Review 5.  The inflammatory response in myocardial infarction.

Authors:  Nikolaos G Frangogiannis; C Wayne Smith; Mark L Entman
Journal:  Cardiovasc Res       Date:  2002-01       Impact factor: 10.787

6.  ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.

Authors:  Chintan Gandhi; Mohammad Moshahid Khan; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2011-11-28       Impact factor: 22.113

7.  Plasma concentration of von Willebrand factor in acute myocardial infarction.

Authors:  H Sakai; S Goto; J Y Kim; N Aoki; S Abe; N Ichikawa; M Yoshida; Y Nagaoka; S Handa
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

8.  ADAMTS13 exerts a thrombolytic effect in microcirculation.

Authors:  Marilena Crescente; Grace M Thomas; Melanie Demers; Jaymie R Voorhees; Siu Ling Wong; Benoit Ho-Tin-Noé; Denisa D Wagner
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

9.  Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury.

Authors:  M R Litt; R W Jeremy; H F Weisman; J A Winkelstein; L C Becker
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

10.  Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog.

Authors:  J L Romson; B G Hook; S L Kunkel; G D Abrams; M A Schork; B R Lucchesi
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more
  49 in total

1.  Relevant role of von Willebrand factor in neutrophil recruitment in a mouse sepsis model involving cecal ligation and puncture.

Authors:  Shogo Kasuda; Hideto Matsui; Shiro Ono; Yasunori Matsunari; Kenji Nishio; Midori Shima; Katsuhiko Hatake; Mitsuhiko Sugimoto
Journal:  Haematologica       Date:  2015-10-22       Impact factor: 9.941

2.  DNase, ADAMTS13, and iPAD4: good for the heart.

Authors:  X Long Zheng
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

3.  Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow.

Authors:  Koya Ozawa; William Packwood; Oleg Varlamov; Yue Qi; Aris Xie; Melinda D Wu; Zaverio Ruggeri; Jose A López; Jonathan R Lindner
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

4.  Noninvasive Evaluation of No-Reflow Phenomenon.

Authors:  Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

5.  VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.

Authors:  Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

6.  Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.

Authors:  Miruna Popa; Sibgha Tahir; Julia Elrod; Su Hwan Kim; Florian Leuschner; Thorsten Kessler; Peter Bugert; Ulrich Pohl; Andreas H Wagner; Markus Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-23       Impact factor: 11.205

Review 7.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

8.  Contribution of ADAMTS13 to the better cell engraftment efficacy in mouse model of bone marrow transplantation.

Authors:  Hideto Matsui; Maiko Takeda; Kenji Soejima; Yasunori Matsunari; Shogo Kasuda; Shiro Ono; Kenji Nishio; Midori Shima; Fumiaki Banno; Toshiyuki Miyata; Mitsuhiko Sugimoto
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

9.  Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions.

Authors:  Yasunori Matsunari; Mitsuhiko Sugimoto; Masaaki Doi; Hideto Matsui; Masahiko Kawaguchi
Journal:  Int J Hematol       Date:  2016-08-25       Impact factor: 2.490

10.  Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.

Authors:  Nirav Dhanesha; Prem Prakash; Prakash Doddapattar; Ira Khanna; Molly J Pollpeter; Manasa K Nayak; Janice M Staber; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-21       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.